The benefits of drug repositioning. Spring 11By Dr Aris Persidis Drugs in development, on the market, or those that are shelved because of lack of efficacy, are excellent starting points for further development. Finding new indications for such drugs w...
|
R&D open verdict? Winter 10By Dr Kay Wardle As pharmaceutical companies begin to shift from in-house R&D to external partnerships and ‘open innovation’, the traditional drug discovery model may soon be a thing of the past. In t...
|
Assessing the value of R&D partnerships. Winter 10By Dr David A Pardoe, Dr Jackie Hunter MBE, Dr Robert M Cooke and Dr Paul Barrett In response to the need to increase the return on investment in R&D, many large Pharma companies are shifting from an internal fixed resource model to more flexible, external relationship...
|
Is the pharmaceutical industry open for innovation? Fall 10By Dr Jackie Hunter CBE Open innovation is the hot topic in many industries and this approach has the potential to make a radical difference to the costs of drug discovery and development in the pharmaceutical i...
|
The Healthcare Industrys Evolving Role in Translational Research an Opportunity for Competitive Advantage. Spring 10By Gregory Venters During the 20th century, medical research has observed enormous advances in basic science discovery, highlighted by the sequencing of the human genome. However, we have not witnessed a co...
|
Maximising the impact of technologies on drug discovery through portfolio management. Winter 09By Charles S. Dormer, Dr Mark Beggs, Dr Lynn Brennan and Roanna London The opportunities to invest in new technologies in drug discovery are broad and extensive. Knowing where to place your investment and ensuring return on these investments is critical to e...
|
|
|
